22-3-eBook-BPInsider-Cover-Border.png

Through the acquisition of Spark therapeutics in 2019, Roche propelled itself into gene therapy space and hasn’t looked back. Reporting from the December 2023 Cell & Gene Therapy Manufacturing & Commercialization Europe conference in Ireland, this eBook addresses the production of next-generation adenoassociated virus (AAV)–based products. Specifically, the Swiss biopharmaceutical giant hopes to break through the manufacturing limitations that have limited the reach of such lifesaving treatments. Roche wants to create a range of gene therapies that can treat large patient populations at affordable prices. BioProcess Insider also brings you the latest trends in AAV-based gene therapy news.

Fill out the form below to read the full eBook now.

You May Also Like